• Judith A. Aberg, MD

• Professor of Medicine

• Principal Investigator, AIDS Clinical Trials Unit

• New York University School of Medicine

• Director of Virology

• Bellevue Hospital Center

• New York, NY

Research Topics

• Immune reconstitution
• Cardiovascular complications of HIV disease

Lecture and Writing Topics

• Opportunistic diseases prevention and treatment
• Cardiovascular complications of HIV disease

Current Professional Summary

Dr Aberg is the Director of Virology at Bellevue Hospital Center and a Professor of Medicine at New York University (NYU). She serves as the principal investigator for the NYU AIDS Clinical Trials Unit and on the editorial boards of several clinical journals. She is an attending physician in infectious diseases and virology.

Committees and Organizations

• Chair-Elect, HIV Medicine Association
• Vice Chair, New York State AIDS Institute Medical Care Committee
• Co-Chair, HIV/AIDS Advisory Committee to the President of New York City Health and Hospital Corporation
• Member, Hepatitis Scientific Committee and Hepatitis Steering Committee, AIDS Clinical Trials Group
• Co-Chair of the National Committee for Quality Assurance (NCQA), AMA, HRSA, HIVMA Consortium of HIV Performance Measures

Honors and Awards

• Linda Lauberstein Award for Clinical Excellence, NY State Dept of Health/AIDS Institute (2008)
• Constance B. Wofsy Women's Health Investigator Award, AIDS Clinical Trials Group (2006)
• AIDS Foundation of St. Louis: Red Ribbon Award (2004)
• John Carey Young Investigator Award, AIDS Clinical Trials Group (2000)

Education

• Pennsylvania State University, College of Medicine, MD (1990)
• Cleveland Clinic Educational Foundation, Internal Medicine Residency (1990-1993); Chief Medical Resident (1993-1994)
• Washington University School of Medicine, Department of Infectious Diseases, Fellow (1994-1996)

Selected Publications

1. Fichtenbaum CJ, Yeh TM, Evans SR, Aberg JA. Treatment with pravastatin and fenofibrate improves atherogenic lipid profiles but not inflammatory markers in ACTG 5087. J Clin Lipidol. 2010;4:279-287.
2. Flexner C, Tierney C, Gross R, et al. Comparison of once-daily versus twice-daily combination antiretroviral therapy in treatment-naive patients: results of AIDS clinical trials group (ACTG) A5073, a 48-week randomized controlled trial. Clin Infect Dis. 2010;50:1041-1052.
3. Horberg MA, Aberg JA, Cheever LW, Renner P, O'Brien Kaleba E, Asch SM. Development of national and multiagency HIV care quality measures. Clin Infect Dis. 2010;51:732-738.
4. Malvestutto CD, Aberg JA. Coronary heart disease in people infected with HIV. Cleve Clin J Med. 2010;77:547-556.
5. Markowitz M, Vaida F, Hare CB, et al. The virologic and immunologic effects of cyclosporine as an adjunct to antiretroviral therapy in patients treated during acute and early HIV-1 infection. J Infect Dis. 2010;201:1298-1302.
6. McComsey GA, Walker UA, Budhathoki CB, et al. Uridine supplementation in the treatment of HIV lipoatrophy: results of ACTG 5229. AIDS. 2010;24:2507-2515.
7. Overton ET, Kang M, Peters MG, et al. Immune response to hepatitis B vaccine in HIV-infected subjects using granulocyte-macrophage colony-stimulating factor (GM-CSF) as a vaccine adjuvant: ACTG study 5220. Vaccine. 2010;28:5597-5604.
8. Thompson MA, Aberg JA, Cahn P, et al. Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International Antiviral Society–USA panel. JAMA. 2010;304:321-333.
9. Tungsiripat M, Kitch D, Glesby MJ, et al. A pilot study to determine the impact on dyslipidemia of adding tenofovir to stable background antiretroviral therapy: ACTG 5206. AIDS. 2010;24:1781-1784.
10. Aberg JA. Cardiovascular complications in HIV management: past, present, and future. JAIDS. 2009;50:54-64.
11. Aberg JA. Lipid management in patients who have HIV and are receiving HIV therapy. Endocrinol Metab Clin North Am. 2009;38:207-222.
12. Aberg JA, Kaplan JE, Libman H, et al. Primary care guidelines for the management of persons infected with human immunodeficiency virus: 2009 update by the HIV medicine Association of the Infectious Diseases Society of America. Clin Infect Dis. 2009;49:651-681.
13. Daskalakis D, Silvera R, Bernstein K, et al. Implementation of HIV testing at 2 New York City bathhouses: from pilot to clinical service. Clin Infect Dis. 2009;48:1609-1616.
14. Lubinski C, Aberg J, Bardeguez AD, et al. HIV policy: the path forward--a joint position paper of the HIV Medicine Association of the Infectious Diseases Society of America and the American College of Physicians. Clin Infect Dis. 2009;48:1335-1344.
15. Tsibris AM, Paredes R, Chadburn A, et al. Lymphoma diagnosis and plasma Epstein-Barr virus load during vicriviroc therapy: results of the AIDS Clinical Trials Group A5211. Clin Infect Dis. 2009;48:642-649.

Return to Top